Also known as: Oxirane, 2,2'-[(1-methylethylidene)bis(4,1-phenyleneoxymethylene)]bis-, 2,2-Bis(p-(2,3-epoxypropoxy)phenyl)propane, 2,2-Bis(4-(2,3-epoxypropyloxy)phenyl)propane, Bis(4-glycidyloxyphenyl)dimethylmethane, 2,2-Bis(p-hydroxyphenyl)propane, diglycidyl ether (+15 more)
CAS 1675-54-3
Bisphenol A diglycidyl ether (CAS 1675-54-3) is a chemical substance with GHS signal word Warning; key hazard signal: H315; H319; H317. Key regulatory status: REACH registered, 7 regulatory/inventory lists, cosmetic ingredient cross-reference; source data from ECHA CLP, EPA ToxValDB, EPA CPDat, AICIS, IARC, ECHA REACH, ILO ICSC.
View cosmetic safety profile for Isopropylidenediphenol Diglycidyl Ether (BADGE) →
Bisphenol A diglycidyl ether is prohibited in EU cosmetics but has active industrial GHS classifications (H315, H319, H317).
CAS, identifiers, formula, and alternate names for the matched substance record.
Carcinogenic hazard classification from IARC monograph evaluations.
| Group | Meaning | Evaluated | Volume |
|---|---|---|---|
| Group 3 | Not classifiable | 1998 | 47, 71 |
EU harmonized hazard classification, hazard statements, pictograms, and signal word.
| Hazard Class | H-Statements | Pictograms | Signal |
|---|---|---|---|
| Skin Irrit. 2; Eye Irrit. 2; Skin Sens. 1 | H315; H319; H317 | GHS07 | Warning |
International Chemical Safety Card hazard and exposure summary.
| Field | Value |
|---|---|
| Short-term Effects | The substance is irritating to the eyes and skin. Exposure could cause lowering of consciousness. |
| Long-term Effects | Repeated or prolonged contact with skin may cause dermatitis. Repeated or prolonged contact may cause skin sensitization. |
| Routes of Exposure | The substance can be absorbed into the body by inhalation of its vapour. |
Industrial and product-use categories associated with this substance.
Inventory, screening, and regulatory list matches from public chemical databases.
| List | Keyword | Source |
|---|---|---|
| drinking_water; Europe; manufacturing; plastic_additive | Belgaqua | CPCat |
| inert_ingredient; non_food_use; Pesticides | EPA | CPCat |
| CEDI | FDA | United States Food and Drug Administration (FDA) |
| Canada; pharmaceutical | DrugBank | DrugBank |
| Canada; pharmaceutical | DrugBank | DrugBank |
| detected; Europe; Toys and children's products | Danish Environmental Protection Agency | Danish EPA |
| detected; Europe; Toys and children's products | Danish Environmental Protection Agency | Danish EPA |
Toxicology endpoints rendered from public NOAEL study rows.
| Value | Unit | Endpoint | Route | Species | Source |
|---|---|---|---|---|---|
| 86.91348115 | uM | AC50 | - | - | NTP_ICE_endocrine |
| 88.41065159 | uM | ACC | - | - | NTP_ICE_endocrine |
| 22.2 | ug/mL | CD54, EC200 | Dermal | - | NTP_ICE_skin_sensitization |
| 9.001 | ug/mL | CD86, EC150 | Dermal | - | NTP_ICE_skin_sensitization |
| 9.91 | ug/mL | CD86, EC150 | Dermal | - | NTP_ICE_skin_sensitization |
| 18.27 | ug/mL | CD86, EC150 | Dermal | - | NTP_ICE_skin_sensitization |
| 25.92 | ug/mL | CV70 | Dermal | - | NTP_ICE_skin_sensitization |
| 36 | ug/mL | CV75 | Dermal | - | NTP_ICE_skin_sensitization |
| =4.93 | mg/m3 | DNEL systemic | inhalation | Human | ToxValDB_GESTIS_DNEL |
| 42.5 | % | Depletion Cys | Dermal | - | NTP_ICE_skin_sensitization |
| 74.8 | % | Depletion Cys | Dermal | - | NTP_ICE_skin_sensitization |
| 1.1 | % | Depletion Lys | Dermal | - | NTP_ICE_skin_sensitization |
| 3.2 | % | Depletion Lys | Dermal | - | NTP_ICE_skin_sensitization |
| 21.8 | % | Depletion Lys + Cys | Dermal | - | NTP_ICE_skin_sensitization |
| 39 | % | Depletion Lys + Cys | Dermal | - | NTP_ICE_skin_sensitization |
| 5 | uM | EC1.5 | Dermal | - | NTP_ICE_skin_sensitization |
| 5.2 | uM | EC1.5 | Dermal | - | NTP_ICE_skin_sensitization |
| 1.5 | % | EC3 | Dermal | Mouse | NTP_ICE_skin_sensitization |
| 8.7 | uM | EC3 | Dermal | - | NTP_ICE_skin_sensitization |
| F3XRM1NX4H | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| F3XRM1NX4H | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| F3XRM1NX4H | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| F3XRM1NX4H | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| 3 | IARC group | IARC carcinogenicity classification | - | - | IARC Monographs |
| 3 | IARC group | IARC carcinogenicity classification | - | - | IARC Monographs |
| 3 | IARC group | IARC carcinogenicity classification | - | - | IARC Monographs |
| 3 | unitless | IARC group | - | - | NTP_ICE_cancer |
| 21.9 | uM | IC50 | Dermal | - | NTP_ICE_skin_sensitization |
| 22 | uM | IC50 | Dermal | - | NTP_ICE_skin_sensitization |
| 12.6 | ratio | Imax | Dermal | - | NTP_ICE_skin_sensitization |
| 13 | ratio | Imax | Dermal | - | NTP_ICE_skin_sensitization |
| =50 | mg/kg bw/day | LEL | oral | Rat | ToxValDB_ECHA_IUCLID |
| =750 | mg/kg bw/day | LEL | oral | Rat | ToxValDB_ECHA_IUCLID |
| =540 | mg/kg bw/day | LOAEL | oral | Rat | ToxValDB_ECHA_IUCLID |
| - | unitless | Model Score | - | - | NTP_ICE_endocrine |
| 0.0243 | unitless | Model Score | - | - | NTP_ICE_endocrine |
| =15 | mg/kg bw/day | NOAEL | oral | Rat | ToxValDB_ECHA_IUCLID |
| =15 | mg/kg bw/day | NOAEL | oral: gavage | Rat | EFSA_OpenFoodTox_EFSA_ReferencePoints.xlsx |
| =15 | mg/kg bw/day | NOAEL | oral: gavage | Rat | EFSA_OpenFoodTox_EFSA_ReferencePoints.xlsx |
| =100 | mg/kg bw/day | NOAEL | oral | Rat | ToxValDB_ECHA_IUCLID |
| =2 | mg/kg bw/day | NOEL | oral | Rat | ToxValDB_ECHA_IUCLID |
| =10 | mg/kg bw/day | NOEL | dermal | Rat | ToxValDB_ECHA_IUCLID |
| =100 | mg/kg bw/day | NOEL | dermal | Rat | ToxValDB_ECHA_IUCLID |
| =750 | mg/kg bw/day | NOEL | oral | Rat | ToxValDB_ECHA_IUCLID |
Showing 44 of 44 studies
Registration status from the ECHA REACH registered substances database.
| Status | Name | EC Number | Link |
|---|---|---|---|
| Registered | 2,2'-[(1-methylethylidene)bis(4,1-phenyleneoxymethylene)]bisoxirane | 216-823-5 | ECHA overview → |
Australian industrial chemicals inventory status and applicable conditions.
Same-CAS cosmetic ingredient record for cross-vertical context.
Same-CAS pharmaceutical records from drug and bioactivity sources.
Same-CAS cannabis compliance and lab records where available.
1 cannabis record found in efsa substances.
View full cannabis profile →Bisphenol A diglycidyl ether (CAS 1675-54-3) is classified under EU CLP Annex VI as Skin Irrit. 2; Eye Irrit. 2; Skin Sens. 1 with signal word Warning. Hazard statements: H315; H319; H317. Source: EU CLP Annex VI (ECHA).
Bisphenol A diglycidyl ether has 44 NOAEL studies in the database. The lowest reported value is 0 unitless. Source: NTP_ICE_endocrine.
Bisphenol A diglycidyl ether appears on 5 regulatory/inventory lists including drinking_water; Europe; manufacturing; plastic_additive, inert_ingredient; non_food_use; Pesticides, CEDI, and 2 more. Source: EPA CPDat.
Bisphenol A diglycidyl ether is classified by IARC as Group 3 — not classifiable as to its carcinogenicity to humans (evaluated 1998). Source: IARC Monographs on the Identification of Carcinogenic Hazards to Humans.
Yes, Bisphenol A diglycidyl ether is also indexed as a cosmetic ingredient under the name Isopropylidenediphenol Diglycidyl Ether (BADGE). View the full cosmetic safety profile on the ingredient page for detailed safety data, SCCS opinions, and regulatory status.
Safety data is sourced from ECHA CLP Annex VI, EPA ToxValDB, EPA CPDat, AICIS (Australian Industrial Chemicals Introduction Scheme), EPA DSSTox, IARC Monographs, ECHA REACH, ILO/WHO ICSC, CosIng / Ingredients DB, ChEMBL / DailyMed, cannabis regulatory/lab databases. All data traces to primary regulatory sources and is updated from official government databases.
Bisphenol A diglycidyl ether is prohibited in EU cosmetics but has active industrial GHS classifications (H315, H319, H317).
Bisphenol A diglycidyl ether also appears in cosmetics, pharmaceutical, cannabis databases.